Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself

Journal of Immunology

Volumn 179, Issue 4, 2007, Pages 2493-2500

  Li, Jiali ^a   Song, Wenru ^a   Czerwinski, Debra K ^a   Varghese, Bindu ^a   Uematsu, Satoshi ^b   Akira, Shizuo ^b   Krieg, Arthur M ^c   Levy, Ronald ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c PFIZER INC   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; TOLL LIKE RECEPTOR 9; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; MOUSE MUTANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9;

EID: 34848856815     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.4.2493     Document Type: Article

References (48)

1. Maloney, D. G. 2005. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J. Clin. Oncol. 23: 6421-6428.
2. Timmerman, J. M., and R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50: 507-529.
3. Timmerman, J. M., and R. Levy. 2000. The history of the development of vaccines for the treatment of lymphoma. Clin. Lymphoma 1: 129-139.
4. Song, W., and R. Levy. 2005. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 65: 5958-5964.
5. Brown, R. D., B. Pope, A. Murray, W. Esdale, D. M. Sze, J. Gibson, P. J. Ho, D. Hart, and D. Joshua. 2001. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 98: 2992-2998.
6. Yurkovetsky, Z. R., G. V. Shurin, D. A. Barry, A. C. Schuh, M. R. Shurin, and P. D. Robbins. 2006. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J. Gene Med. 8: 129-137.
7. Brunner, C., J. Seiderer, A. Schlamp, M. Bidlingmaier, A. Eigler, W. Haimerl, H. A. Lehr, A. M. Krieg, G. Hartmann, and S. Endres. 2000. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. 165: 6278-6286.
8. Krieg, A. M. 1995. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol. 15: 284-292.
9. Jahrsdörfer, B., G. Hartmann, E. Racila, W. Jackson, L. Mühlenhoff, G. Meinhardt, S. Endres, B. K. Link, A. M. Krieg, and G. J. Weiner. 2001. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukocyte Biol. 69: 81-88.
10. Hartmann, G., G. J. Weiner, and A. M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96: 9305-9310.
11. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
12. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
13. Smith, K. S., J. W. Rhee, and M. L. Cleary. 2002. Transformation of bone marrow B-cell progenitors by E2A-HLF requires coexpression of Bcl-2. Mol. Cell Biol. 22: 7678-7687.
14. Vollmer, J., R. D. Weeratna, M. Jurk, H. L. Davis, C. Schetter, M. Wüllner, T. Wader, M. Liu, A. Kritzler, and A. M. Krieg. 2004. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J. Leukocyte Biol. 76: 585-593.
15. Yi, A. K., M. Chang, D. W. Peckham, A. M. Krieg, and R. F. Ashman. 1998. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160: 5898-5906.
16. Link, B. K., Z. K. Ballas, D. Weisdorf, J. E. Wooldridge, A. D. Bossler, M. Shannon, W. L. Rasmussen, A. M. Krieg, and G. J. Weiner. 2006. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29: 558-568.
17. Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484.
18. Jahrsdörfer, B., J. E. Wooldridge, S. E. Blackwell, C. M. Taylor, T. S. Griffith, B. K. Link, and G. J. Weiner. 2005. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukocyte Biol. 77: 378-387.
19. Weigel, B. J., D. A. Rodeberg, A. M. Krieg, and B. R. Blazar. 2003. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9: 3105-3114.
20. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
21. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868.
22. Taieb, J., N. Chaput, N. Schartz, S. Roux, S. Novault, C. Menard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jeze, F. Lemonnier, and L. Zitvogel. 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176: 2722-2729.
23. Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167: 4878-4886.
24. Baines, J., and E. Celis. 2003. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin. Cancer Res. 9: 2693-2700.
25. Blander, J. M., and R. Medzhitov. 2006. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440: 808-812.
26. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
27. Boog, C., J. Boes, and C. Melief. 1988. Role of dendritic cells in the regulation of class I restricted cytotoxic T lymphocyte responses. J. Immunol. 140: 3331-3337.
28. Cui, Y., E. Kelleher, E. Straley, E. Fuchs, K. Gorski, H. Levitsky, I. Borrello, C. I. Civin, S. P. Schoenberger, L. Cheng, D. M. Pardoll, and K. A. Whartenby. 2003. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. 9: 952-958.
29. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4: 1009-1015.
30. Sauter, B., M. L. Albert, L. Francisco, M. Larsson, S. Somersan, and N. Bhardwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191: 423-434.
31. Datta, S. K., V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170: 4102-4110.
32. + T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
33. Sparwasser, T., R. M. Vabulas, B. Villmow, G. B. Lipford, and H. Wagner. 2000. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30: 3591-3597.
34. + T cells. J. Immunol. 174: 710-717.
35. Cornet, S., J. Menez-Jamet, F. Lemonnier, K. Kosmatopoulos, and I. Miconnet. 2006. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. Vaccine 24: 1880-1888.
36. Rodríguez-Pinto, D. 2005. B cells as antigen presenting cells. Cell. Immunol. 238: 67-75.
37. Pozzi, L.-A. M., J. W. Maciaszek, and K. L. Rock. 2005. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J. Immunol. 175: 2071-2081.
38. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6: 722-727.
39. Allison, J. P., A. A. Hurwitz, and D. R. Leach. 1995. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7: 682-686.
40. Briones, J., J. M. Timmerman, D. L. Panicalli, and R. Levy. 2003. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J. Natl. Cancer Inst. 95: 548-555.
41. Colombo, M. P., and G. Forni. 1994. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15: 48-51.
42. Decker, T., S. Hipp, R. J. Kreitman, I. Pastan, C. Peschel, and T. Licht. 2002. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 99: 1320-1326.
43. Spencer, J., and R. Kubo. 1989. Mixed isotype class II antigen expression: a novel class II molecule is expressed on a murine B cell lymphoma. J. Exp. Med. 169: 625-640.
44. Glimcher, L., K. Kim, I. Green, and W. Paul. 1982. Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J. Exp. Med. 155: 445-459.
45. Chen, W., Y. Yu, C. Shao, M. Zhang, W. Wang, L. Zhang, and X. Cao. 2001. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody. Immunol. Lett. 77: 17-23.
46. Rieger, R., and T. J. Kipps. 2003. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 63: 4128-4135.
47. Kaisho, T., and S. Akira. 2001. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol. 22: 78-83.
48. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13: 114-119.